Yarrow Bioscience Inc YARW
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
-
Yarrow Bioscience Announces Proposed Underwritten Public Offering
-
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
Trading Information
- Previous Close Price
- $19.82
- Day Range
- $18.40–20.16
- 52-Week Range
- $0.32–44.28
- Bid/Ask
- $16.25 / $29.75
- Shares Outstanding
- 9.30M
- Market Cap
- $156.96M
- Volume/Avg
- 99,832 / 412,433
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.yarrowbioscience.com
Valuation
|
Metric
|
YARW
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
YARW
|
|---|---|
Quick Ratio | 14.87 |
Current Ratio | 15.26 |
Interest Coverage | — |
Quick Ratio
YARW
Profitability
|
Metric
|
YARW
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
No chart available
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%vhZF$? | LOCK|NL!J | $123B | |||
| Moderna Inc
MRNA
| LOCK|xh!Qp^ | LOCK|@@F | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|N%?V>M | LOCK|sp!&? | $78B | |||
| argenx SE ADR
ARGX
| LOCK|<@&>@c@ | LOCK|Fz | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&@<@?X? | LOCK|dl | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@?Xp#m | LOCK|KrTVz | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|x!^%L?# | LOCK|<?$#$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|#hMLQH< | LOCK|M$ | $22B | |||
| Incyte Corp
INCY
| LOCK|&&x<?G | LOCK|>$% | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|M?WMLCq | LOCK|t?X | $14B |
United States